De definitieve gids voor genbewerking.
★
Menu
Home Leren Nieuws
Verkennen Technologieën Ziekten Behandelingen Klinische onderzoeken Bedrijven Wetenschappers Genen Onderzoek Instellingen
Verder dan geneeskunde Landbouw Ethiek Investeren Wereldkaart
Leren & Tools Begin hier Woordenlijst A–Z Vergelijk technologieën Tijdlijn Lijsten & Rankings AI-agents ★ Opgeslagen API
Over Over ons Methodologie Databronnen Redactioneel beleid Contact Disclaimers

Begeleide weergave
Nieuw in de genetica? We leggen elk begrip uit terwijl je bladert, in gewone taal. Dezelfde pagina's, met de hulp ingebouwd.

Expertvisie
Je kent de biologie al. Alleen de inhoud, helder en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Lichte modus

Companies

Public Gene-Editing Companies

Gene-editing companies with listed shares, as held in CRISPR Decoded.

Hoe deze lijst is samengesteld

Companies in CRISPR Decoded that have shares traded on a public exchange. CRISPR Decoded does not carry share prices or market capitalisations. Those change constantly, and a stale figure is worse than none.

#VermeldingCategorie Status
1 CRISPR Therapeutics Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR… CRISPR-Cas9 platform Approved
2 Intellia Therapeutics Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human… In vivo CRISPR platform Phase III
3 Beam Therapeutics Founded by David Liu and colleagues to commercialise base editing: precision changes to… Base editing platform Phase III
4 Editas Medicine One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes… In vivo editing Preclinical
5 Prime Medicine Founded to commercialise prime editing, and the company behind the first published… Prime editing platform Phase I/II
6 Verve Therapeutics Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025… In vivo base editing Phase II
7 Caribou Biosciences Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing… Cell therapy Phase I
8 Sana Biotechnology Engineering transplanted cells to be invisible to the immune system, so they can be given… Cell engineering Phase I
9 Scribe Therapeutics Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the… Engineered editors Preclinical
10 Mammoth Biosciences Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit… Miniature editors and diagnostics Preclinical
11 Arbor Biotechnologies Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at… Novel editors Phase I
12 Vertex Pharmaceuticals The established biotechnology company that partnered on, and commercialises, the first… Large biotechnology Approved
13 bluebird bio A pioneer of lentiviral gene addition with several approved therapies, and a cautionary… Gene addition Approved
14 Tessera Therapeutics Developing 'gene writing': mobile genetic elements repurposed to insert whole sequences… Gene writing Preclinical
15 Tune Therapeutics Turning genes up and down without changing sequence: epigenetic editing taken into early… Epigenetic editing Phase I
16 Sangamo Therapeutics The company that took gene editing into humans first, years before CRISPR existed as a… Zinc finger platform Phase III
17 Eli Lilly and Company A major pharmaceutical company that entered gene editing by acquisition, buying Verve… Large pharmaceutical Phase II
Wat deze lijst je niet verteltEducational information only, not investment advice, and not a complete list of listed gene-editing companies. Nothing here is a recommendation regarding any security.
Written by CRISPR Decoded editorial team Last updated Oct 27, 2026